Author:
Kim Hye Jin,Kim Hwang-Phill,Yoon Young-Kwang,Kim Maeng-Sup,Lee Gwan-Sun,Han Sae-Won,Im Seock-Ah,Kim Tae-You,Oh Do-Youn,Bang Yung-Jue
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Pharmacology (medical),Pharmacology,Oncology
Reference60 articles.
1. Cell signaling by receptor tyrosine kinases.;Schlessinger;Cell,2000
2. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.;Guy;Proc Natl Acad Sci USA,1994
3. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.;Ciardiello;Clin Cancer Res,2000
4. CI-1033, a pan-erbB tyrosine kinase inhibitor.;Slichenmyer;Semin Oncol,2001
5. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) corrected.;Fukuoka;J Clin Oncol,2003
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献